Twist Bioscience Co. (NASDAQ:TWST) Receives Consensus Rating of "Moderate Buy" from Brokerages

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $54.40.

Several equities research analysts recently issued reports on the stock. Robert W. Baird lifted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a report on Tuesday, February 4th. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the company an "overweight" rating in a report on Monday, February 3rd. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, TD Cowen reiterated a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th.

Twist Bioscience Price Performance

TWST stock traded up $0.26 during mid-day trading on Thursday, hitting $38.82. The stock had a trading volume of 935,132 shares, compared to its average volume of 881,875. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 52 week low of $27.41 and a 52 week high of $60.90. The firm has a market capitalization of $2.32 billion, a P/E ratio of -11.49 and a beta of 1.87. The firm has a fifty day simple moving average of $47.45 and a 200 day simple moving average of $45.60.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period last year, the firm earned ($0.75) EPS. The business's quarterly revenue was up 24.1% compared to the same quarter last year. As a group, research analysts forecast that Twist Bioscience will post -2.12 EPS for the current year.

Insider Transactions at Twist Bioscience

In other news, Director Robert Chess sold 3,504 shares of Twist Bioscience stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $51.85, for a total value of $181,682.40. Following the completion of the sale, the director now owns 21,641 shares in the company, valued at $1,122,085.85. The trade was a 13.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Paula Green sold 860 shares of Twist Bioscience stock in a transaction on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00. Following the completion of the sale, the senior vice president now owns 133,715 shares of the company's stock, valued at $7,046,780.50. This represents a 0.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,180 shares of company stock worth $1,821,971. Company insiders own 3.01% of the company's stock.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in shares of Twist Bioscience in the 4th quarter worth $58,000. Westwood Holdings Group Inc. bought a new stake in shares of Twist Bioscience in the 4th quarter worth $657,000. Teza Capital Management LLC bought a new stake in shares of Twist Bioscience in the 4th quarter worth $204,000. Sherbrooke Park Advisers LLC bought a new stake in shares of Twist Bioscience in the 4th quarter worth $238,000. Finally, ProShare Advisors LLC grew its stake in shares of Twist Bioscience by 30.5% in the 4th quarter. ProShare Advisors LLC now owns 19,226 shares of the company's stock worth $893,000 after acquiring an additional 4,488 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.